MYOFORMIN
LIVE

Serial Number

99092562

Owner

Emmyon, Inc.

Attorney

Erica M Hines

Filing Date

Mar 19, 2025

Add to watchlist:

No watchlists yet
View on USPTO

MYOFORMIN Trademark

Serial Number: 99092562

MYOFORMIN is a trademark filed by Emmyon, Inc. on March 19, 2025. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

Emmyon, Inc. (2 trademarks)

2746 Foxwoods Ln SW
Rochester, MN 55902

Entity Type: 03

Trademark Details

Filing Date

March 19, 2025

Registration Date

Not Registered

Published for Opposition

September 16, 2025

Goods & Services

Pharmaceutical preparations for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Pharmaceutical preparations for the prevention of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, bariatric surgery, or conditions that accompany treatment with weight loss medications; or conditions or complications associated with any of the foregoing; Nutraceuticals for the treatment of skeletal muscle atrophy, sarcopenia, cachexia, muscular weakness, fatigue, obesity, diabetes, oncological disorders, hematological disorders, cancer, conditions associated with aging, heart failure, COPD, end stage renal failure, cirrhosis, critical illness, spinal cord injury, stroke, Parkinson's disease, Alzheimer's disease, rheumatoid arthritis, autoimmune disorders, Cushing's syndrome, hypogonadism, osteoarthritis, orthopedic injuries, HIV/AIDS, chronic infection, diseases and conditions associated with bariatric surgery, or conditions that accompany treatment with weight loss medications; Nutraceuticals for use as a dietary supplement for inhibiting muscle atrophy, inhibiting sarcopenia, inhibiting muscular weakness, inhibiting fatigue, inhibiting obesity, inhibiting diabetes, promoting muscle health, promoting muscular strength

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 29, 2026 EXRA
SOU EXTENSION 1 GRANTED
Apr 28, 2026 EX1G
SOU EXTENSION 1 FILED
Apr 28, 2026 EXT1
SOU TEAS EXTENSION RECEIVED
Apr 28, 2026 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Nov 11, 2025 NOAM
POST PUBLICATION AMENDMENT - ENTERED
Oct 25, 2025 CHPB
ASSIGNED TO PETITION STAFF
Oct 23, 2025 APET
TEAS POST PUBLICATION AMENDMENT RECEIVED
Sep 16, 2025 EPPA
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Sep 16, 2025 NPUB
PUBLISHED FOR OPPOSITION
Sep 16, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Sep 10, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Aug 20, 2025 CNSA
ASSIGNED TO EXAMINER
Aug 19, 2025 DOCK
APPLICATION FILING RECEIPT MAILED
Mar 19, 2025 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Mar 19, 2025 NWOS
NEW APPLICATION ENTERED
Mar 19, 2025 NWAP